Intero Biosystems, a biotechnology startup, is positioning its lab-grown human intestinal models as a viable alternative for pharmaceutical drug testing. As global regulatory bodies increasingly seek to reduce or eliminate the reliance on animal models in medical research, the company is focusing on scaling its organoid technology to meet industrial demand.

Organoids are miniature, simplified versions of organs grown in a laboratory setting that mimic the structure and function of human tissue. By using these models, drugmakers may be able to observe how human cells react to new compounds more accurately than they could through traditional animal testing. Intero Biosystems is currently working to expand its production capabilities to supply these biological tools to the broader pharmaceutical market. While the move aligns with a growing trend in the biotech industry to move away from animal trials, the company faces the challenge of proving that these lab-grown models can consistently replicate complex human biological responses at a scale required for large-scale drug development.